close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Enveric Biosciences

< Previous 1 2 Next >
News headline image
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Patent Granted for Drug Candidate
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Participate in BIO International Convention 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
From Enveric Biosciences
Via Business Wire
Tickers CSE:MBIO ENVB
News headline image
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)
From Enveric Biosciences
Via Business Wire
Tickers ENVB
News headline image
Enveric Biosciences to Present at the Centurion One 5th Global Summit
From Enveric Biosciences
Via Business Wire
Tickers ENVB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today